Android app Apple app link

Genmab A/S (GMAB) Analyst Forecast

NASDAQ Currency in USD Disclaimer
Add to Alerts ADD TO LIST

$0.00

$0 (0%)
Last update: 07:00 PM EST
Day's range
$26.55
Day's range
$27.32

Recent Analyst Forecasts and Stock Ratings

Date Brokerage Firm Analyst Name Price Target Price when Posted Upside/Downside
on Report Date		 Details
02/23/2026 Guggenheim Michael Schmidt $40.00 $29.29   36.57%
02/17/2026 Jefferies Benjamin Jackson $41.50 $30.03   38.2%
11/06/2025 Truist Financial Asthika Goonewardene $48.00 $28.84   66.44%
10/06/2025 Truist Financial Asthika Goonewardene $49.00 $33.56   46.01%
09/29/2025 Leerink Partners Jonathan Chang $34.00 $29.16   16.61%
09/23/2025 Guggenheim Michael Schmidt $43.00 $28.60   50.35%
03/11/2025 Truist Financial Asthika Goonewardene $45.00 $20.26   122.11%
09/03/2024 Morgan Stanley Vikram Purohit $31.00 $27.41   13.1%
08/09/2024 BMO Capital Etzer Darout $46.00 $27.07   69.93%
06/27/2024 BTIG Kaveri Pohlman $47.00 $25.67   83.09%
06/27/2024 H.C. Wainwright Raghuram Selvaraju $50.00 $25.71   94.48%
06/04/2024 Truist Financial Asthika Goonewardene $53.00 $28.83   83.84%
02/23/2024 BMO Capital Etzer Darout $48.00 $29.16   64.61%
11/28/2022 Morgan Stanley Matthew Harrison $34.00 $44.83   -24.16%

Genmab FAQ's

Genmab has been rated by research analysts at H.C. Wainwright, Wolfe Research, Guggenheim, Jefferies, Truist Financial, Leerink Partners in the past 90 days.

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.